Paper Details

  1. Home
  2. Paper Details

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.

Author: ChironC, DulacO, MarchandM C, PonsG, ReyE, TranA, VincentJ, d'AthisP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Stiripentol, a cytochrome P450 inhibitor, showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in an open study. A randomized, placebo-controlled trial confirmed these results in 41 children with SMEI.
Paper Details　
Original Abstract of the Article :
Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on tria...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(00)03157-3

データ提供：米国国立医学図書館（NLM）

Stiripentol for Severe Myoclonic Epilepsy in Infancy: A Randomized Trial

The challenges faced by families dealing with severe myoclonic epilepsy in infancy (SMEI) are immense, and researchers are constantly searching for effective treatments. This randomized, placebo-controlled trial investigates the efficacy of stiripentol, an inhibitor of cytochrome P450, as an add-on therapy for SMEI in conjunction with clobazam and valproate.

Stiripentol's Potential for Seizure Control

The study found that stiripentol, when added to the standard treatment regimen, showed a statistically significant reduction in seizure frequency compared to placebo. This finding suggests that stiripentol could be a valuable addition to the treatment arsenal for SMEI.

Improving Outcomes for Children with SMEI

The research highlights the potential of stiripentol to improve outcomes for children with SMEI. It's like finding a reliable source of water in a desert, providing much-needed relief and hope for families facing this challenging condition.

Dr.Camel's Conclusion

This study offers encouraging evidence for the use of stiripentol as an add-on therapy for SMEI. While further research is needed to optimize its use, stiripentol holds promise for improving seizure control and enhancing the quality of life for children with this severe epilepsy syndrome.

Date :
  1. Date Completed 2000-12-13
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

11089822

DOI: Digital Object Identifier

10.1016/s0140-6736(00)03157-3

Related Literature

Article Analysis
・Side Effects of stiripentol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.